Cwm LLC Purchases 46 Shares of Becton, Dickinson and Company (NYSE:BDX)

Cwm LLC lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,303 shares of the medical instruments supplier’s stock after buying an additional 46 shares during the quarter. Cwm LLC’s holdings in Becton, Dickinson and Company were worth $1,537,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in BDX. CX Institutional lifted its holdings in Becton, Dickinson and Company by 3.0% during the 3rd quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock valued at $385,000 after purchasing an additional 43 shares during the last quarter. Aaron Wealth Advisors LLC lifted its holdings in Becton, Dickinson and Company by 23.7% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 1,169 shares of the medical instruments supplier’s stock valued at $302,000 after purchasing an additional 224 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its holdings in Becton, Dickinson and Company by 21.1% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 2,859 shares of the medical instruments supplier’s stock valued at $739,000 after purchasing an additional 499 shares during the last quarter. Investment Research & Advisory Group Inc. lifted its holdings in Becton, Dickinson and Company by 1.2% during the 3rd quarter. Investment Research & Advisory Group Inc. now owns 8,601 shares of the medical instruments supplier’s stock valued at $2,224,000 after purchasing an additional 105 shares during the last quarter. Finally, Ropes Wealth Advisors LLC lifted its holdings in Becton, Dickinson and Company by 1.8% during the 3rd quarter. Ropes Wealth Advisors LLC now owns 9,058 shares of the medical instruments supplier’s stock valued at $2,342,000 after purchasing an additional 157 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Up 0.5 %

BDX opened at $231.55 on Friday. The company has a market capitalization of $66.89 billion, a P/E ratio of 54.87, a P/E/G ratio of 1.93 and a beta of 0.43. The stock has a fifty day moving average of $239.24 and a 200-day moving average of $241.42. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. Becton, Dickinson and Company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.98 earnings per share. On average, equities analysts expect that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BDX. Barclays lifted their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Raymond James lifted their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.